Search Results
Oct 29, 2025, 12:43 ET Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
2025. The new data highlight and underscore the differentiated profile of CONTRAVE® (naltrexone HCl/bupropion HCl) as an oral, non-GLP-1, combination therapy that helps adults manage weight by reducing appetite and supporting sustainable, long-term outcomes. "During
More news about: Currax Pharmaceuticals LLC
Oct 29, 2025, 10:30 ET Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
immunology. The enhanced facility will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year. This strategic expansion
More news about: Eli Lilly and Company
Oct 29, 2025, 10:30 ET Lilly anuncia una inversión de más de 1,200 millones de dólares en su planta de Puerto Rico para aumentar la capacidad de manufactura de medicamentos orales en Estados Unidos
La planta será una de las instalaciones que manufacturará orforglipron, el primer agonista del receptor GLP-1 oral de molécula pequeña de Lilly, que la compañía planifica someter antes de finalizar el año a las agencias regulatorias globales para el tratamiento
More news about: Eli Lilly and Company
Oct 29, 2025, 09:28 ET Registration Now Open for the NKF 2026 Spring Clinical Meetings
Home Dialysis and POCUS Essentials for Nephrologists. Engaging lunch workshops including: The Skinny on GLP1-RAs, Transplant Care for the General Nephrologist, Real-world Applications of Artificial Intelligence in Nephrology, and more.
More news about: The National Kidney Foundation
Oct 29, 2025, 08:33 ET Amid Policy Shifts and Tariffs, SHARx Unshackles U.S. Rx Delivery System
bracing for health insurance cost increases nearing 10% by 2026—the steepest increase in more than 15 years—fueled by skyrocketing demand for GLP-1's, chronic disease prevalence, and new pharmaceutical tariffs. (2,3)
More news about: SHARx
Oct 29, 2025, 07:00 ET LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
LillyDirect's direct-to-consumer pricing, or self-pay pricing, offers a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity. Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting
More news about: Eli Lilly and Company
Oct 29, 2025, 02:03 ET Insilico Showcases Advanced Generative Biologics Engine in Breakthrough 72-Hour Peptide Design Targeting GLP1R for Cardiometabolic Disease
design peptides targeting GLP1R—the receptor modulated by blockbuster diabetes drugs such as Ozempic. Leveraging its Biology42: Generative Biologics engine, Insilico's R&D team generated over 5,000 novel peptides within a 72-hour cycle, without referencing any known GLP1R binders. From these, 20
More news about: Insilico Medicine
Oct 28, 2025, 22:00 ET Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University
1) Validate the safety and efficacy of a GLP-grade LmCen-/- vaccine produced by Gennova Biopharmaceuticals under cGMP conditions using preclinical animal models,
More news about: GHIT Fund
Oct 28, 2025, 22:00 ET Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University
1) Validate the safety and efficacy of a GLP-grade LmCen-/- vaccine produced by Gennova Biopharmaceuticals under cGMP conditions using preclinical animal models,
More news about: GHIT Fund
Oct 28, 2025, 10:01 ET Glucagon-Like Peptide-1 Analogues Market to Surpass USD 299.08 Billion by 2033, Fueled by the Weight Management and Diabetes Revolution | DataM Intelligence
on 'GLP-1 Analogues Market' 79 – Tables73 – Figures215 – Pages Market Segmentation Analysis The global GLP-1 analogues
More news about: DataM Intelligence 4 Market Research LLP
Oct 28, 2025, 10:00 ET TCI Biotech to Showcase Leadership as the "Liquid Expert" at SupplySide Global 2025, Featuring Clinically-Proven Innovations for Weight Management and Metabolic Health
2025 | Time: 10:30–10:50 AM Featured Study: GLP-1 Support FormulaThis proprietary botanical formulation is designed to maintain healthy glucagon-like peptide-1 (GLP-1) levels. In a human study, participants demonstrated an average reduction of
More news about: TCI; TCI Biotech
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
The partnership will accelerate efficient and sustainable manufacturing of high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
accelerate efficient and sustainable manufacturing of high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
dysfunction-associated steatohepatitis ( MASH)Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
dysfunction-associated steatohepatitis ( MASH)Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis
More news about: NOVO NORDISK INC.
Oct 28, 2025, 06:00 ET InstantGMP Launches Fully Integrated Laboratory Information Management System (LIMS) software
LIMS solutions that require complex and costly integration with ERP, MES, or EBR systems, InstantGMP's LIMS is purpose-built for GMP manufacturers and GLP laboratories. Delivered as part of the InstantGMP PRO SaaS platform, it brings together Quality, Inventory, Production, and Documentation in one compliant
More news about: InstantGMP, Inc.
Oct 27, 2025, 11:45 ET MENU-ORDER AI Launches October 28 to Help Restaurants Win Back GLP-1 Diners
High-protein, GLP-1 friendly, low-carb, and low Weight Watchers (WW) points options tailored to users' goals. Featuring restaurants on MENU – ORDER AI helps them reach three fast-growing diner segments: GLP-1 users
More news about: MENU - ORDER AI
Oct 27, 2025, 08:39 ET Supergut Launches at Walmart Nationwide
and GLP-1 Daily Support fiber blends were developed to help consumers power their wellness by starting with the gut. While both fiber blends are rooted in Supergut's premium ingredient approach to gut health, Foundational Daily Fiber and the GLP-1 Daily Support
More news about: Supergut
Oct 27, 2025, 08:31 ET MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Oct 27, 2025, 08:00 ET New Lifesum Survey: GLP-1s Reduce Cravings for Ultra-Processed Foods -- But Nutrition Remains Key
GLP-1 medications like Ozempic, Wegovy, and Mounjaro may be reshaping eating habits. Over half (51%) of users reported that these drugs help them resist ultra- processed foods (UPFs) — snacks, sweets, and convenience meals that dominate modern diets — highlighting the potential of GLP-1s to
More news about: Lifesum
Oct 27, 2025, 08:00 ET Prime Therapeutics to present latest managed care pharmacy insights at AMCP Nexus 2025
Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care EAGAN, Minn., Oct. 27, 2025 /PRNewswire/
More news about: Prime Therapeutics
Oct 27, 2025, 07:34 ET Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion
and 48 clinical trial approvals were granted during the period, with four programs admitted to breakthrough-therapy designation lists. The GLP-1/GIP dual agonist HRS9531 reported positive Phase III topline results in weight management, advancing one of the company's key late-stage metabolic
More news about: Hengrui Pharma
Oct 27, 2025, 06:00 ET Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m., EST Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants
More news about: Ascletis Pharma Inc.
Oct 27, 2025, 06:00 ET 歌禮將攜ASC30口服片、ASC30注射劑和ASC31與ASC47聯合療法的研究結果亮相2025年肥胖周（ObesityWeek®）
歌禮小分子和多肽肥胖症管線將進行多項壁報展示 - 口服 GLP-1R 小分子激動劑 ASC30 的 28 天多劑量遞增研究完整分析
More news about: 歌禮製藥有限公司
Oct 26, 2025, 20:00 ET Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
GLP-1 receptor agonists have become a key therapeutic option for type 2 diabetes—particularly for patients with comorbid obesity—owing to their benefits, including glycemic control, weight reduction, and cardiorenal protection. As the world's first approved GCG/GLP-1 dual receptor
More news about: Innovent Biologics